High sensitivity and clonal stability of the genomic fusion as single marker for response monitoring in ETV6-RUNX1-positive acute lymphoblastic leukemia.
Jana HoffmannManuela KrumbholzHelia Pimentel GutiérrezMarion FilliesAnnabell SzymanskyKirsten BleckmannUdo Zur StadtRolf KöhlerRoland P KuiperMartin HorstmannArend von StackelbergCornelia EckertMarkus MetzlerPublished in: Pediatric blood & cancer (2019)
ETV6-RUNX1 fusion sites are highly sensitive and reliable MRD markers. Our data confirm that they are unaffected by clonal evolution and selection during front-line and second-line chemotherapy in contrast to Ig/TCR rearrangements, which require several markers per patient to compensate for the observed loss of target clones. In future studies, the genomic ETV6-RUNX1 fusion can be used as single MRD marker.
Keyphrases
- current status
- acute lymphoblastic leukemia
- transcription factor
- allogeneic hematopoietic stem cell transplantation
- magnetic resonance
- copy number
- case report
- regulatory t cells
- gene expression
- electronic health record
- big data
- dna methylation
- locally advanced
- magnetic resonance imaging
- radiation therapy
- computed tomography
- fluorescent probe
- data analysis
- molecularly imprinted
- simultaneous determination
- chemotherapy induced